Drugs / SGB-9768
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06501573 | Aug 2024 → May 2025 overdue | — | Suzhou Sanegene Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06786338 | Apr 2025 → Jul 2026 overdue | IgA glomerulonephritis, complement 3 glomerulopathy, immunoglobulin-mediated membranoproliferative glomerulonephritis | Suzhou Sanegene Bio Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGB-9768 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06786338 ↗ |
| Route | Subcutaneous | “SGB-9768 for sc injection” NCT06501573 ↗ |